Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07165028 · ClinicalTrials.gov registry record · Phase 3
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
A Phase 3 study of Metabolic Dysfunction Associated Steatotic Liver Disease, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 4,500
- Enrollment target
- 20
- Study locations
NCT07165028 is a Phase 3 study of Metabolic Dysfunction Associated Steatotic Liver Disease that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 4,500 participants, above the 97-participant average among 7 other Metabolic Dysfunction Associated Steatotic Liver Disease trials with a reported enrollment target (4539% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT07165028, a Phase 3 study of Metabolic Dysfunction Associated Steatotic Liver Disease, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 4,500 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The study will enroll adults who have MASLD based on non-invasive tests (NITs), which indicate they are more likely to develop MALO. Participants will be randomly assigned within a Master Protocol to receive either retatrutide (N1T-MC-RT01), tirzepatide (N1T-MC-TZ01) or placebo. The trial plans to enroll about 4,500 adults and will run for approximately 224 weeks. Participants may have up to approximately 25 to 30 clinic visits throughout the study to monitor their health, complete study procedures, and assess liver function and disease progression. Once the study is complete, eligible participants may participate in an optional 2-year extension study, in which all participants will receive either retatrutide or tirzepatide, even if they received placebo in the main study.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tirzepatide
- DRUG Retatrutide
Study Locations (20)
California
- San Fernando Valley Health Institute - Canoga Park
- Ark Clinical Research - Fountain Valley - Fountain Valley
- Fresno Clinical Research Center - Fresno
- UCSD - Altman Clinical and Translational Research Institute (ACTRI) - La Jolla
- Orange County Research Center - Lake Forest
- Om Research LLC - Lancaster
- Ark Clinical Research - Long Beach
- Los Angeles Institute for Metabolic Research - Los Angeles
- United Medical Doctors - Murrieta - Murrieta
- Knowledge Research Center - Orange
- California Liver Research Center - Pasadena
- Artemis Institute for Clinical Research - Riverside
Arizona
- The Institute for Liver Health II dba Arizona Clinical Trials - Chandler - Chandler
- Spectrum Research Institute - Gilbert
- The Institute for Liver Health II dba Arizona Liver Health - Peoria - Peoria
- Epic Medical Research-Sun City - Sun City
- The Institute for Liver Health II dba Arizona Clinical Trials - Tucson - Tucson
- Del Sol Research Management, LLC - Tucson
Alabama
- MFA Clinical Research - Tuscaloosa
Arkansas
- Arkansas Gastroenterology - North Little Rock - North Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,500 participants |
| Start Date | 2025-10-15 |
| Est. Completion | 2032-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07165028
The ClinicalTrials.gov registry entry for NCT07165028 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 4,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 97-participant average among 7 other Metabolic Dysfunction Associated Steatotic Liver Disease trials with a reported enrollment target (4539% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metabolic Dysfunction Associated Steatotic Liver Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07165028 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT07165028 about?
NCT07165028 is a clinical study titled "A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)". The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The study will enroll adults who have MASLD based on non-invasi...
What is the current status of trial NCT07165028?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 4,500 participants. The study started on 2025-10-15. Estimated completion is 2032-08.
What conditions does trial NCT07165028 study?
This clinical trial studies the following conditions: Metabolic Dysfunction Associated Steatotic Liver Disease.
What interventions are being tested in trial NCT07165028?
The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG), Retatrutide (DRUG).
Who is sponsoring clinical trial NCT07165028?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07165028 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metabolic Dysfunction Associated Steatotic Liver Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Non-Invasive Diagnostic Tests for MASLD in Pediatric Population
RECRUITING · NA
-
Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
RECRUITING · NA
-
Influence of Metabolic Syndrome on Endogenous Oxalate Synthesis
RECRUITING · NA
-
Quantitative Ultrasound(DeepUSFF) vs MRI-PDFF for Liver Fat Assessment in MASLD
RECRUITING · NA
-
Feasibility of the Paso Program for Patients With Metabolic Dysfunction Associated Steatotic Liver Disease
ACTIVE NOT RECRUITING · NA
-
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.